Clicky

Reneo Pharmaceuticals, Inc.(RPHM)

Description: Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.


Keywords: Clinical Trial Clinical Research Stage Pharmaceutical Carboxylic Acids Transcription Factors Intracellular Receptors Mitochondrial Disease

Home Page: reneopharma.com

RPHM Technical Analysis

18575 Jamboree Road
Irvine, CA 92612
United States
Phone: 858 283 0280


Officers

Name Title
Mr. Michael G. Grey Founder & Exec. Chairman
Mr. Gregory J. Flesher Pres, CEO & Director
Mr. Michael P. Cruse Chief Operating Officer
Mr. Vineet R. Jindal Consultant
Ms. Jennifer P. Lam Principal Financial & Accounting Officer
Ms. Wendy S. Johnson M.B.A. Consultant
Dr. Alejandro Dorenbaum M.D. Chief Medical Officer
Ms. Lynn Purkins Ph.D. Sr. VP of Clinical Operations
Ms. Ashley F. Hall J.D. Chief Devel. Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4685
Price-to-Sales TTM: 0
IPO Date: 2021-04-08
Fiscal Year End: December
Full Time Employees: 32
Back to stocks